ID   MOLM-14
AC   CVCL_7916
SY   Molm-14; Molm 14; Molm14; MOLM14
DR   BTO; BTO_0005720
DR   EFO; EFO_0022446
DR   Cell_Model_Passport; SIDM00436
DR   ChEMBL-Cells; CHEMBL3706571
DR   ChEMBL-Targets; CHEMBL3706570
DR   Cosmic; 787418
DR   Cosmic; 1150898
DR   Cosmic; 1281333
DR   DepMap; ACH-001574
DR   DSMZ; ACC-777
DR   DSMZCellDive; ACC-777
DR   GEO; GSM2037134
DR   GEO; GSM2037135
DR   GEO; GSM3145574
DR   GEO; GSM3145724
DR   JCRB; JCRB1812
DR   Lonza; 978
DR   PubChem_Cell_line; CVCL_7916
DR   Wikidata; Q54906323
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9305600;
RX   PubMed=12529668;
RX   PubMed=21552520;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: 3-4 days (PubMed=9305600); ~50 hours (DSMZ=ACC-777).
CC   Sequence variation: Gene fusion; HGNC; HGNC:7132; KMT2A + HGNC; HGNC:7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=9305600).
CC   Sequence variation: Mutation; HGNC; HGNC:3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=12529668).
CC   Omics: Genomics; ChIP-seq; H3K79me1.
CC   Omics: Proteomics; PTM; Phosphorylation; Quantitative.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): COG; DepMap=ACH-001574; DSMZ=ACC-777; JCRB=JCRB1812
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 10,11
ST   D16S539: 10,11
ST   D18S51: 13,15
ST   D19S433: 12,14
ST   D21S11: 30,31
ST   D2S1338: 23,25
ST   D3S1358: 15
ST   D5S818: 10,11
ST   D7S820: 10,12
ST   D8S1179: 13,14
ST   FGA: 21,23
ST   Penta D: 9,12
ST   Penta E: 18,19
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2119 ! MOLM-13
SX   Male
AG   20Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 14-08-25; Version: 29
//
RX   PubMed=12529668; DOI=10.1038/sj.leu.2402740;
RA   Quentmeier, Hilmar
RA   Reinhardt, Julia
RA   Zaborski, Margarete
RA   Drexler, Hans Gunther
RT   "FLT3 mutations in acute myeloid leukemia cell lines.";
RL   Leukemia 17:120-124(2003).
//
RX   PubMed=9305600; DOI=10.1038/sj.leu.2400768;
RA   Matsuo, Yoshinobu
RA   MacLeod, Roderick A.F.
RA   Uphoff, Cord C.
RA   Drexler, Hans Gunther
RA   Nishizaki, Chiharu
RA   Katayama, Yoshio
RA   Kimura, Genki
RA   Fujii, Nobuharu
RA   Omoto, Eijiro
RA   Harada, Mine
RA   Orita, Kunzo
RT   "Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14)
RT   with interclonal phenotypic heterogeneity showing MLL-AF9 fusion
RT   resulting from an occult chromosome insertion,
RT   ins(11;9)(q23;p22p23).";
RL   Leukemia 11:1469-1477(1997).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler, Hans Gunther
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=21552520; DOI=10.1371/journal.pone.0019169; PMCID=PMC3084268;
RA   Gu, Ting-Lei
RA   Nardone, Julie
RA   Wang, Yi
RA   Loriaux, Marc
RA   Villen, Judit
RA   Beausoleil, Sean A.
RA   Tucker, Meghan
RA   Kornhauser, Jon M.
RA   Ren, Jian-Min
RA   MacNeill, Joan
RA   Gygi, Steven P.
RA   Druker, Brian Jay
RA   Heinrich, Michael Charles
RA   Rush, John
RA   Polakiewicz, Roberto D.
RT   "Survey of activated FLT3 signaling in leukemia.";
RL   PLoS ONE 6:e19169.1-e19169.10(2011).
//